Skip to main content
editor.ajphr@gmail.com
9409046853
e-ISSN: 2321-3647
American Journal of Pharmacy and Health Research

American Journal of Pharmacy and Health Research

LoginTrack Your Paper
Published

Semaglutide: Pharmacology and Clinical Evidence in Cardiometabolic Therapy

, ,

Published in October 2026 Issue 10 (Vol. 14, Issue 10, 2026)

Semaglutide: Pharmacology and Clinical Evidence in Cardiometabolic Therapy - Issue cover

Keywords

glucagon-like peptide-1 receptor agonisttype 2 diabetes mellitusobesitycardiovascular outcomeschronic kidney disease

Abstract

Background: Type 2 diabetes mellitus and obesity frequently coexist and contribute to cardiovascular and renal complications. Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, has expanded incretin pharmacology beyond glucose lowering toward broader cardiometabolic therapy. Methods: This narrative review integrated pharmacological and clinical evidence on semaglutide. Priority was given to pivotal randomized controlled trials, cardiovascular and renal outcome trials, pharmacokinetic studies and clinically relevant follow-up studies from the SUSTAIN, PIONEER, STEP, SELECT and FLOW programmes. Results: Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, reduces appetite and energy intake, and delays gastric emptying. Once-weekly subcutaneous and once-daily oral formulations produced clinically important reductions in glycated hemoglobin and body weight. Semaglutide reduced major adverse cardiovascular events in high-risk patients with type 2 diabetes, lowered cardiovascular events in patients with established cardiovascular disease and obesity without diabetes, and slowed chronic kidney disease progression in patients with diabetes and chronic kidney disease. Gastrointestinal adverse effects were the main tolerability limitation, and substantial weight regain occurred after treatment withdrawal. Conclusion: Semaglutide is an important cardiometabolic therapy; optimal use requires patient selection, gradual dose escalation, monitoring and long-term treatment planning.

References

  1. [1]1. Anderson SL, Trujillo JM. Advances in pharmacologic treatment of type 2 diabetes mellitus: semaglutide and other GLP-1 receptor agonists. Clin Pharmacokinet 2018; 57: 1529-1538.
  2. [2]2. Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015; 58: 7370-7380.
  3. [3]3. Granhall C, Sondergaard FL, Thomsen M, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet 2019; 58: 781-791.
  4. [4]4. Marbury TC, Flint A, Jacobsen JB, Derving Karsbol J, Lasseter K. Pharmacokinetics and tolerability of a once-weekly subcutaneous dose of semaglutide in subjects with and without renal impairment. Clin Pharmacokinet 2017; 56: 1381-1390.
  5. [5]5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844.
  6. [6]6. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841-851.
  7. [7]7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002.
  8. [8]8. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389: 2221-2232.
  9. [9]9. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391: 109-121.
  10. [10]10. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022; 24: 1553-1564.
  11. [11]11. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med 2025; 393: 1077-1087.

Authors (3)

Shruti M Aher

JSPMs Rajarshi Shahu college O...

View all publications →

Tanvi Vasudev Kulkarni

JSPMs Rajarshi Shahu college O...

View all publications →

Suyog Ishwar Jawale

SPMs Rajarshi Shahu college Of...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 0.4 MB
Format: PDF
ViewDownload

Summarise this paper with AI:

GoogleGooglePerplexityPerplexityGrokGrokChatGPTChatGPTClaudeClaude

Article Information

Published in:

October 2026 Issue 10 (Vol. 14, Issue 10, 2026)

AJPHR10140002

AJPHR-01-000969

9-17

2026-10-25

JATS XML

Article Impact

Views:2,940
Downloads:759

How to Cite

Aher, S. M., Vasudev Kulkarni, T., & Ishwar Jawale, S. (2026). Semaglutide: Pharmacology and Clinical Evidence in Cardiometabolic Therapy. American Journal of Pharmacy and Health Research, 14(10), 9-17. https://ajphr.com/articles/AJPHR10140002

Article Actions

Whatsapp